Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections. Anidulafungin is a well tolerated echinocandin with a favorable pharmacokinetic profile; in particular, its lack of hepatic metabolism and renal excretion enables drug administration without dosage adjustment to subjects with any degree of impaired hepatic or renal function. This simplifies dosing, with a requirement for only once-daily administration and a lack of drug-drug interactions in patients who require multiple medications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2165/11315580-000000000-00000 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic and Phenotypic Intra-Clade Variation in Candida auris Isolated from Critically Ill Patients in a New York City Tertiary Care Center.
Clin Chem
January 2025
Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, United States.
Background: Candida auris is an emerging multidrug-resistant pathogen. Interpretation of susceptibility testing can be difficult since minimum inhibitory concentration (MIC) breakpoints have not been fully established.
Methods: All C.
Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis.
Front Pharmacol
December 2024
Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
Article Synopsis
- This meta-analysis examines the effectiveness and safety of combining echinocandins with standard antifungal treatments for invasive aspergillosis infection (IAI).
- Ten studies with 1,100 patients were reviewed, comparing outcomes like clinical cure rates, mortality, and adverse drug reactions between combination therapy and standard monotherapy.
- Results showed no significant differences in clinical cure rates or mortality between the two approaches, but there indicated a trend towards better outcomes for those receiving echinocandins alongside standard care, with similar safety profiles.
Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations.
Clin Pharmacokinet
December 2024
Pharmacy Service, Division of Medicines, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
In recent years, many population pharmacokinetic (popPK) models have been developed for echinocandins to better understand the pharmacokinetics (PK) of these antifungals. This comprehensive review aimed to summarize popPK models of echinocandins (micafungin, caspofungin, anidulafungin, and rezafungin), by focusing on dosage optimization to maximize the probability of attaining the PK/PD target proposed in special populations. A search in PubMed, Embase, Web of Science, and Scopus, supplemented by the bibliography of relevant articles, was conducted from inception to March 2024, including both observational and prospective trials.
View Article and Find Full Text PDFAntibacterial and antifungal drug concentrations in intra-abdominal abscesses: a prospective clinical study.
Antimicrob Agents Chemother
December 2024
Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Secondary peritonitis with intra-abdominal abscesses (IAA) is difficult to treat because of the supposed low rate of penetration of antimicrobial drugs at the site of infection. However, clinical data about the actual bioavailability of antimicrobial drugs in IAA are scarce. This prospective observational study aimed at assessing the drug penetration in IAA of the antibiotics (piperacillin-tazobactam, carbapenems) and antifungals (fluconazole, echinocandins) that are usually recommended for the treatment of intra-abdominal infections.
View Article and Find Full Text PDFDetecting Echinocandin Resistance in C. glabrata Using Commercial Methods: Are CLSI or EUCAST Breakpoints Suitable for Categorical Classification?
Mycoses
November 2024
Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
Background: Previous studies correlated Sensititre YeastOne and gradient diffusion plastic strips with standard procedures for the detection of echinocandin-resistant C. glabrata isolates. However, these studies were limited by the low number of resistant isolates studied; the inclusion of sufficient numbers of mutant isolates is essential to test the procedures' capacity to detect resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!